Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study
Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Qunming Dong, Nolan Campbell, Stephanie Licata, Pei‐Ran Ho (2018). 086 The rapid efficacy of natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): results from reveal, a randomised, head-to-head study. , 89(6), DOI: https://doi.org/10.1136/jnnp-2018-anzan.85.
Article50 days agoNatalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study
Stephanie Licata, Helmut Butzkueven, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Q. Dong, Nolan Campbell, Pei‐Ran Ho (2017). Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study. , 381, DOI: https://doi.org/10.1016/j.jns.2017.08.703.
Article50 days agoNatalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study
Helmut Butzkueven, Stephanie Licata, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Sourav Santra, Nolan Campbell, Pei‐Ran Ho (2020). Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study. , 10(10), DOI: https://doi.org/10.1136/bmjopen-2020-038861.
Article50 days ago